0001367644-23-000071.txt : 20230306
0001367644-23-000071.hdr.sgml : 20230306
20230306193708
ACCESSION NUMBER: 0001367644-23-000071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230302
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kramer Robert
CENTRAL INDEX KEY: 0001380956
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 23710620
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
wf-form4_167814941740129.xml
FORM 4
X0306
4
2023-03-02
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380956
Kramer Robert
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
1
1
0
0
President and CEO
Common Stock
2023-03-02
4
A
0
19231
0
A
255289
D
Common Stock
2023-03-02
4
A
0
38462
0
A
293751
D
Employee Stock Options (Right to Buy)
12.06
2023-03-02
4
A
0
38462
0
A
2030-03-01
Common Stock
38462.0
258182
D
Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Represents the corrected number of securities owned due to a computational error on prior Form-4.
Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
/s/ Jennifer Lynn Fox, Attorney-in-fact
2023-03-06